{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:25:39Z","timestamp":1794655539330,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_141179"],"award-info":[{"award-number":["320030_141179"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008947","name":"Stiftung Synapsis - Alzheimer Forschung Schweiz AFS","doi-asserted-by":"publisher","award":["2017-PI01"],"award-info":[{"award-number":["2017-PI01"]}],"id":[{"id":"10.13039\/501100008947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer\u2019s disease (AD) pathology and predict clinical progression in a memory clinic setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma NfL and p-tau181, along with established cerebrospinal fluid (CSF) biomarkers of AD pathology, were measured in participants with normal cognition (CN) and memory clinic patients with cognitive impairment (mild cognitive impairment and dementia, CI). Clinical and neuropsychological assessments were performed at inclusion and follow-up visits at 18 and 36\u2009months. Multivariate analysis assessed associations of plasma NfL and p-tau181 levels with AD, single CSF biomarkers, hippocampal volume, and clinical measures of disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma NfL levels were higher in CN participants with an AD CSF profile (defined by a CSF p-tau181\/A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \u2009&gt;\u20090.0779) as compared with CN non-AD, while p-tau181 plasma levels were higher in CI patients with AD. Plasma NfL levels correlated with CSF tau and p-tau181 in CN, and with CSF tau in CI patients. Plasma p-tau181 correlated with CSF p-tau181 in CN and with CSF tau, p-tau181, A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      , and A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      in CI participants. Compared with a reference model, adding plasma p-tau181 improved the prediction of AD in CI patients while adding NfL did not. Adding p-tau181, but not NfL levels, to a reference model improved prediction of cognitive decline in CI participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of cerebral AD pathology and cognitive decline. Their predictive performance depends on the presence of cognitive impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00805-8","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T15:07:49Z","timestamp":1616684869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-7702","authenticated-orcid":false,"given":"Christopher","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Lewczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Richiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Mar\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"6","key":"805_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O\u2019Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 2018;136(6):821\u201353. https:\/\/doi.org\/10.1007\/s00401-018-1932-x .","journal-title":"Acta Neuropathol"},{"issue":"11","key":"805_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14(11):639\u201352. https:\/\/doi.org\/10.1038\/s41582-018-0079-7 .","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"805_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366 Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/28346578\/.","journal-title":"JAMA Neurol"},{"issue":"1","key":"805_CR4","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"Y-S Lin","year":"2018","unstructured":"Lin Y-S, Lee W-J, Wang S-J, Fuh J-L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 2018;8(1):17368. https:\/\/doi.org\/10.1038\/s41598-018-35766-w .","journal-title":"Sci Rep"},{"issue":"1","key":"805_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, Maler JM, Kornhuber J, Blennow K, Zetterberg H. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):71. https:\/\/doi.org\/10.1186\/s13195-018-0404-9 .","journal-title":"Alzheimers Res Ther"},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, Zhang X, Alzheimer\u2019s Disease Neuroimaging Initiative. Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett. 2017;650:60\u20134. https:\/\/doi.org\/10.1016\/j.neulet.2017.04.027 .","journal-title":"Neurosci Lett"},{"issue":"7","key":"805_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765 .","journal-title":"JAMA Neurol"},{"issue":"8","key":"805_CR8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381 Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/30967444\/.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"805_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, Jack CR Jr, Petersen RC, Dage JL. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013 .","journal-title":"Alzheimers Dement"},{"issue":"5","key":"805_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Sch\u00f6ll M, Massarweh G, Soucy JP, H\u00f6glund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5 .","journal-title":"Lancet Neurol"},{"issue":"3","key":"805_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2 .","journal-title":"Nat Med"},{"issue":"3","key":"805_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1 .","journal-title":"Nat Med"},{"key":"805_CR13","doi-asserted-by":"crossref","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry. 2020;26:429\u201342(2021).","DOI":"10.1038\/s41380-020-00923-z"},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.exger.2017.10.013","volume":"100","author":"J Mathys","year":"2017","unstructured":"Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer\u2019s pathology in MCI and mild dementia. Exp Gerontol. 2017;100:45\u201353 Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/29054536\/.","journal-title":"Exp Gerontol"},{"issue":"11","key":"805_CR15","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/WNL.43.11.2412-a .","journal-title":"Neurology"},{"issue":"3","key":"805_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment\u2014beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240\u20136. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01380.x .","journal-title":"J Intern Med"},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbi.2017.01.020","volume":"62","author":"J Popp","year":"2017","unstructured":"Popp J, Oikonomidi A, Tautvydait\u0117 D, Dayon L, Bacher M, Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL. Markers of neuroinflammation associated with Alzheimer\u2019s disease pathology in older adults. Brain Behav Immun. 2017;62:203\u201311. https:\/\/doi.org\/10.1016\/j.bbi.2017.01.020 .","journal-title":"Brain Behav Immun"},{"issue":"12","key":"805_CR18","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jalz.2018.06.2857","volume":"14","author":"GL Bowman","year":"2018","unstructured":"Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, Henry H, Oikonomidi A, Migliavacca E, Bacher M, Popp J. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018;14(12):1640\u201350. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.2857 .","journal-title":"Alzheimers Dement"},{"issue":"6","key":"805_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595\u20139. https:\/\/doi.org\/10.1038\/nbt.1641 .","journal-title":"Nat Biotechnol"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nicl.2014.11.001","volume":"7","author":"D Schmitter","year":"2015","unstructured":"Schmitter D, Roche A, Mar\u00e9chal B, Ribes D, Abdulkadir A, Bach-Cuadra M, Daducci A, Granziera C, Kl\u00f6ppel S, Maeder P, Meuli R, Krueger G, Alzheimer's Disease Neuroimaging Initiative. An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer\u2019s disease. Neuroimage Clin. 2015;7:7\u201317. https:\/\/doi.org\/10.1016\/j.nicl.2014.11.001 .","journal-title":"Neuroimage Clin"},{"issue":"2","key":"805_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/mrm.21992","volume":"62","author":"B Mortamet","year":"2009","unstructured":"Mortamet B, Bernstein MA, Jack CR, Gunter JL, Ward C, Britson PJ, et al. Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med. 2009;62(2):365\u201372. https:\/\/doi.org\/10.1002\/mrm.21992 .","journal-title":"Magn Reson Med"},{"issue":"6","key":"805_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH, Visser P-J, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid \u201cAlzheimer profile\u201d: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713\u201323 e2.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"805_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 .","journal-title":"Alzheimers Dement"},{"issue":"10","key":"805_CR24","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O, the Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med. 2016;8(10):1184\u201396. https:\/\/doi.org\/10.15252\/emmm.201606540 .","journal-title":"EMBO Mol Med"},{"key":"805_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.dadm.2019.05.001","volume":"11","author":"S Fossati","year":"2019","unstructured":"Fossati S, Ramos Cejudo J, Debure L, Pirraglia E, Sone JY, Li Y, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2019;11:483\u201392.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"805_CR26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"C-C Yang","year":"2018","unstructured":"Yang C-C, Chiu M-J, Chen T-F, Chang H-L, Liu B-H, Yang S-Y. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J Alzheimers Dis. 2018;61(4):1323\u201332. https:\/\/doi.org\/10.3233\/JAD-170810 .","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"805_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and Down syndrome. Mol Neurodegener. 2017;12(1):63. https:\/\/doi.org\/10.1186\/s13024-017-0206-8 .","journal-title":"Mol Neurodegener"},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.dadm.2019.08.002","volume":"11","author":"AL Benedet","year":"2019","unstructured":"Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, et al. Plasma neurofilament light associates with Alzheimer\u2019s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst). 2019;11:679\u201389.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"805_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-020-00601-w","volume":"12","author":"AJ Ehrenberg","year":"2020","unstructured":"Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, Mattsson-Carlgren N, Ashton NJ, Hanrieder J, Zetterberg H, Sch\u00f6ll M, Paterson RW. Relevance of biomarkers across different neurodegenerative diseases. Alzheimers Res Ther. 2020;12(1):56. https:\/\/doi.org\/10.1186\/s13195-020-00601-w .","journal-title":"Alzheimers Res Ther"},{"key":"805_CR30","doi-asserted-by":"crossref","unstructured":"Guzm\u00e1n-V\u00e9lez E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, Sanchez JS, Baena A, et al. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer\u2019s disease. Alzheimers Dement. 2021. Online ahead of print.","DOI":"10.1002\/alz.12248"},{"issue":"1","key":"805_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13195-020-00697-0","volume":"12","author":"L He","year":"2020","unstructured":"He L, de Souto Barreto P, Aggarwal G, Nguyen AD, Morley JE, Li Y, et al. Plasma A\u03b2 and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimers Res Ther. 2020;12(1):128. https:\/\/doi.org\/10.1186\/s13195-020-00697-0 .","journal-title":"Alzheimers Res Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00805-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-021-00805-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00805-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T15:08:10Z","timestamp":1616684890000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00805-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00805-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-135649\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with applicable laws and regulations, the local ethics committee approved this study (No. 171\/2013), and all participants or their legal representatives provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PL received consultation and\/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, and Roche. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JR owns shares in Siemens healthcare. JP received consultation and speaker honoraria from Nestle Institute of Health Sciences, Innovation Campus, EPFL, Lausanne, Switzerland, Ono Pharma, OM Pharma Suisse and from Fujirebio Europe. The other authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}